CN1215070C - 前胡丙素在制备治疗肿瘤药物中的应用 - Google Patents
前胡丙素在制备治疗肿瘤药物中的应用 Download PDFInfo
- Publication number
- CN1215070C CN1215070C CN 01143860 CN01143860A CN1215070C CN 1215070 C CN1215070 C CN 1215070C CN 01143860 CN01143860 CN 01143860 CN 01143860 A CN01143860 A CN 01143860A CN 1215070 C CN1215070 C CN 1215070C
- Authority
- CN
- China
- Prior art keywords
- cell
- compound
- mdr
- medicine
- apc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 64
- 150000001875 compounds Chemical class 0.000 title claims abstract description 63
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 31
- 230000000259 anti-tumor effect Effects 0.000 title abstract description 7
- 238000000034 method Methods 0.000 title abstract description 7
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 17
- 229960000641 zorubicin Drugs 0.000 claims description 29
- FBTUMDXHSRTGRV-ALTNURHMSA-N zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 claims description 29
- 238000002360 preparation method Methods 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 11
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 claims description 4
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 claims description 4
- 229940044683 chemotherapy drug Drugs 0.000 claims description 4
- 229940122255 Microtubule inhibitor Drugs 0.000 claims description 3
- 231100000782 microtubule inhibitor Toxicity 0.000 claims description 3
- 230000001399 anti-metabolic effect Effects 0.000 claims description 2
- 230000006907 apoptotic process Effects 0.000 abstract description 18
- 230000001939 inductive effect Effects 0.000 abstract description 4
- 230000002195 synergetic effect Effects 0.000 abstract description 3
- 230000000973 chemotherapeutic effect Effects 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 87
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 53
- 101001017818 Homo sapiens ATP-dependent translocase ABCB1 Proteins 0.000 description 38
- 229940079593 drug Drugs 0.000 description 24
- 230000000694 effects Effects 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 15
- 230000002147 killing effect Effects 0.000 description 12
- 238000011160 research Methods 0.000 description 11
- 201000011510 cancer Diseases 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- ZGFASEKBKWVCGP-UHFFFAOYSA-N cyclocoumarol Chemical compound C12=CC=CC=C2OC(=O)C2=C1OC(OC)(C)CC2C1=CC=CC=C1 ZGFASEKBKWVCGP-UHFFFAOYSA-N 0.000 description 8
- 238000002512 chemotherapy Methods 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 231100000433 cytotoxic Toxicity 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- XGPBRZDOJDLKOT-UHFFFAOYSA-N praeruptorin A Natural products C1=CC(=O)OC2=C1C=CC1=C2C(OC(C)=O)C(OC(=O)C(C)=CC)C(C)(C)O1 XGPBRZDOJDLKOT-UHFFFAOYSA-N 0.000 description 6
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 5
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- 230000001186 cumulative effect Effects 0.000 description 5
- 230000001472 cytotoxic effect Effects 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 229940088024 isoptin Drugs 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 238000011275 oncology therapy Methods 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 102000007469 Actins Human genes 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 4
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical group C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 4
- 206010059866 Drug resistance Diseases 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- PHHAXWBLJNBVNS-UHFFFAOYSA-N Isoglycycoumarin Natural products C=1C=2C(OC)=C3CCC(C)(C)OC3=CC=2OC(=O)C=1C1=CC=C(O)C=C1O PHHAXWBLJNBVNS-UHFFFAOYSA-N 0.000 description 4
- LPGWZGMPDKDHEP-HLTPFJCJSA-N Leurosine Chemical compound C([C@]1([C@@H]2O1)CC)N(CCC=1C3=CC=CC=C3NC=11)C[C@H]2C[C@]1(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC LPGWZGMPDKDHEP-HLTPFJCJSA-N 0.000 description 4
- LYUZYPKZQDYMEE-KNXUDURGSA-N Peucedanocoumarin II Natural products C1=CC(=O)OC2=C3[C@@H](OC(=O)C(/C)=C/C)[C@H](OC(C)=O)C(C)(C)OC3=CC=C21 LYUZYPKZQDYMEE-KNXUDURGSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 230000008485 antagonism Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229960003048 vinblastine Drugs 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 229960003328 benzoyl peroxide Drugs 0.000 description 3
- IAQRGUVFOMOMEM-UHFFFAOYSA-N butene Natural products CC=CC IAQRGUVFOMOMEM-UHFFFAOYSA-N 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 238000006073 displacement reaction Methods 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- GVBNSPFBYXGREE-UHFFFAOYSA-N (10-acetyloxy-8,8-dimethyl-2-oxo-9,10-dihydropyrano[2,3-f]chromen-9-yl) 2-methylbutanoate Chemical compound C1=CC(=O)OC2=C1C=CC1=C2C(OC(C)=O)C(OC(=O)C(C)CC)C(C)(C)O1 GVBNSPFBYXGREE-UHFFFAOYSA-N 0.000 description 2
- YJGVMLPVUAXIQN-LGWHJFRWSA-N (5s,5ar,8ar,9r)-5-hydroxy-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-LGWHJFRWSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- ZPSJGADGUYYRKE-UHFFFAOYSA-N 2H-pyran-2-one Chemical group O=C1C=CC=CO1 ZPSJGADGUYYRKE-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- UYNCFCUHRNOSCN-FYYLOGMGSA-N N-[(1R,2R)-1-hydroxy-3-(4-morpholinyl)-1-phenylpropan-2-yl]decanamide Chemical compound C([C@@H](NC(=O)CCCCCCCCC)[C@H](O)C=1C=CC=CC=1)N1CCOCC1 UYNCFCUHRNOSCN-FYYLOGMGSA-N 0.000 description 2
- 241001254606 Peucedanum praeruptorum Species 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 229940123237 Taxane Drugs 0.000 description 2
- 229940122803 Vinca alkaloid Drugs 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- LYUZYPKZQDYMEE-JZWAJAMXSA-N [(9s,10r)-9-acetyloxy-8,8-dimethyl-2-oxo-9,10-dihydropyrano[2,3-f]chromen-10-yl] (z)-2-methylbut-2-enoate Chemical compound C1=CC(=O)OC2=C3[C@@H](OC(=O)C(\C)=C/C)[C@H](OC(C)=O)C(C)(C)OC3=CC=C21 LYUZYPKZQDYMEE-JZWAJAMXSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000002730 additional effect Effects 0.000 description 2
- 229940045799 anthracyclines and related substance Drugs 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 238000005100 correlation spectroscopy Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000013016 damping Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 2
- 125000004185 ester group Chemical group 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 150000002305 glucosylceramides Chemical class 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000002831 pharmacologic agent Substances 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000012313 reversal agent Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- LYUZYPKZQDYMEE-RTBURBONSA-N (+)-cis-3-acetyl-4-angeloylkhellactone Natural products C1=CC(=O)OC2=C3[C@@H](OC(=O)C(C)=CC)[C@@H](OC(C)=O)C(C)(C)OC3=CC=C21 LYUZYPKZQDYMEE-RTBURBONSA-N 0.000 description 1
- VRYALKFFQXWPIH-RANCGNPWSA-N (3r,4s,5r)-3,4,5,6-tetrahydroxy-2-tritiohexanal Chemical compound O=CC([3H])[C@@H](O)[C@H](O)[C@H](O)CO VRYALKFFQXWPIH-RANCGNPWSA-N 0.000 description 1
- VRYALKFFQXWPIH-PBXRRBTRSA-N (3r,4s,5r)-3,4,5,6-tetrahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)CC=O VRYALKFFQXWPIH-PBXRRBTRSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000004791 1D NOESY Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical group CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 1
- 102100028186 ATP-binding cassette sub-family C member 5 Human genes 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- PNTWXEIQXBRCPS-UHFFFAOYSA-N Calipteryxin Natural products C1=CC(=O)OC2=C3C(OC(=O)C(C)=CC)C(OC(=O)C(C)=CC)C(C)(C)OC3=CC=C21 PNTWXEIQXBRCPS-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 241000125183 Crithmum maritimum Species 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000001157 Fourier transform infrared spectrum Methods 0.000 description 1
- 101000986622 Homo sapiens ATP-binding cassette sub-family C member 5 Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- GVBNSPFBYXGREE-SYURPWHHSA-N Peucedanocoumarin I Natural products O=C(O[C@H]1[C@H](OC(=O)C)c2c3OC(=O)C=Cc3ccc2OC1(C)C)[C@H](CC)C GVBNSPFBYXGREE-SYURPWHHSA-N 0.000 description 1
- IBSXOQJJZICENO-UHFFFAOYSA-N Pteryxin Natural products CC=C(OC1C(OC(=O)C)C(C)(C)Oc2ccc3C=CC(=O)Oc3c12)/C(=O)O IBSXOQJJZICENO-UHFFFAOYSA-N 0.000 description 1
- LYUZYPKZQDYMEE-YRCPKEQFSA-N Pteryxin Chemical compound C1=CC(=O)OC2=C3[C@@H](OC(=O)C(\C)=C/C)[C@@H](OC(C)=O)C(C)(C)OC3=CC=C21 LYUZYPKZQDYMEE-YRCPKEQFSA-N 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- UFUVJROSOIXJGR-IULGZIFLSA-N [(9r,10r)-8,8-dimethyl-10-(3-methylbutanoyloxy)-2-oxo-9,10-dihydropyrano[2,3-f]chromen-9-yl] (z)-2-methylbut-2-enoate Chemical compound C1=CC(=O)OC2=C1C=CC1=C2[C@@H](OC(=O)CC(C)C)[C@@H](OC(=O)C(\C)=C/C)C(C)(C)O1 UFUVJROSOIXJGR-IULGZIFLSA-N 0.000 description 1
- XGPBRZDOJDLKOT-NXIDYTHLSA-N [(9s,10s)-10-acetyloxy-8,8-dimethyl-2-oxo-9,10-dihydropyrano[2,3-f]chromen-9-yl] (z)-2-methylbut-2-enoate Chemical compound C1=CC(=O)OC2=C1C=CC1=C2[C@H](OC(C)=O)[C@H](OC(=O)C(\C)=C/C)C(C)(C)O1 XGPBRZDOJDLKOT-NXIDYTHLSA-N 0.000 description 1
- PNTWXEIQXBRCPS-FNCQTZNRSA-N [8,8-dimethyl-9-[(e)-2-methylbut-2-enoyl]oxy-2-oxo-9,10-dihydropyrano[2,3-f]chromen-10-yl] (e)-2-methylbut-2-enoate Chemical compound C1=CC(=O)OC2=C3C(OC(=O)C(/C)=C/C)C(OC(=O)C(\C)=C\C)C(C)(C)OC3=CC=C21 PNTWXEIQXBRCPS-FNCQTZNRSA-N 0.000 description 1
- -1 acetoxyl group Chemical group 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 208000020990 adrenal cortex carcinoma Diseases 0.000 description 1
- 208000007128 adrenocortical carcinoma Diseases 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- PMMURAAUARKVCB-UHFFFAOYSA-N alpha-D-ara-dHexp Natural products OCC1OC(O)CC(O)C1O PMMURAAUARKVCB-UHFFFAOYSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000012984 antibiotic solution Substances 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 150000007860 aryl ester derivatives Chemical group 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 101150036080 at gene Proteins 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 208000027119 bilirubin metabolic disease Diseases 0.000 description 1
- 230000002902 bimodal effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 125000000332 coumarinyl group Chemical group O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003684 drug solvent Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 208000036796 hyperbilirubinemia Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000299 mutagenicity Toxicity 0.000 description 1
- 230000007886 mutagenicity Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- OAHKWDDSKCRNFE-UHFFFAOYSA-N phenylmethanesulfonyl chloride Chemical compound ClS(=O)(=O)CC1=CC=CC=C1 OAHKWDDSKCRNFE-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- UFUVJROSOIXJGR-UHFFFAOYSA-N qianhucoumarin H Natural products C1=CC(=O)OC2=C1C=CC1=C2C(OC(=O)CC(C)C)C(OC(=O)C(C)=CC)C(C)(C)O1 UFUVJROSOIXJGR-UHFFFAOYSA-N 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000003375 selectivity assay Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000012982 x-ray structure analysis Methods 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
原子 | x | y | z | Beq(2) |
O(1)O(2)O(3)O(4)O(5)O(6)O(7)O(8)O(9)O(10)O(11)O(12)O(13)O(14)C(1)C(2)C(3)C(4)C(5)C(6)C(7)C(8)C(9)C(10)C(11)C(12)C(13)C(14)C(15)C(16)C(17)C(18)C(19) | 0.5357(2)0.6434(2)0.2935(2)0.3229(2)0.4087(2)0.3963(2)0.4795(2)0.0832(2)0.0067(2)0.2437(2)0.1275(2)0.0049(2)0.0437(2)-0.0746(2)0.6006(3)0.6092(3)0.5564(3)0.4892(3)0.4807(2)0.4168(2)0.3593(3)0.3669(3)0.4307(3)0.4117(2)0.3458(3)0.2711(3)0.2318(3)0.2129(3)0.3595(3)0.3252(4)0.2555(4)0.3515(5)0.4139(5) | 0.2238(2)0.3242(3)0.0293(2)0.1420(2)0.0406(3)0.2705(2)0.2854(3)-0.1473(2)-0.0259(3)-0.3933(2)-0.3134(2)-0.3320(3)-0.2159(2)-0.2819(3)0.2663(4)0.2383(4)0.1768(4)0.1343(4)0.1612(3)0.1278(3)0.0657(3)0.0350(4)0.0694(4)0.1567(4)0.0933(3)0.0827(4)0.1882(4)0.0051(4)0.1089(5)0.1708(5)0.2537(5)0.1556(6)0.0843(6) | 1.0456(1)1.0569(2)1.0253(1)1.2066(1)1.2770(2)1.1187(1)1.2229(2)1.2334(1)1.2735(2)1.1235(1)1.0118(1)0.9504(2)1.0988(1)1.1172(2)1.0171(3)0.9444(3)0.9047(2)0.9342(2)1.0048(2)1.0384(2)0.9982(2)0.9274(2)0.8964(2)1.1158(2)1.1431(2)1.0887(2)1.0661(2)1.1159(3)1.2716(3)1.3303(3)1.3044(3)1.3957(4)1.4271(3) | 4.42(7)6.04(9)4.97(8)4.72(8)7.9(1)4.25(7)6.89(10)4.12(7)5.87(9)4.14(7)4.34(7)7.0(1)4.23(7)7.9(1)4.8(1)5.4(1)5.1(1)4.2(1)3.8(1)3.8(1)4.2(1)5.1(1)5.0(1)4.1(1)4.2(1)4.3(1)5.2(1)6.0(1)5.5(2)7.2(2)8.8(2)9.7(3)9.7(2) |
C(20)C(21)C(22)C(23)C(24)C(25)C(26)C(27)C(28)C(29)C(30)C(31)C(32)C(33)C(34)C(35)C(36)C(37)C(38)C(39)C(40)C(41)C(42)H(1)H(2)H(3)H(4)H(5)H(6)H(7)H(8)H(9)H(10)H(11)H(12)H(13)H(14)H(15)H(16)H(17)H(18) | 0.4351(3)0.4124(3)0.0726(3)0.1421(3)0.2131(3)0.2233(2)0.1563(2)0.1585(2)0.2320(2)0.3011(2)0.2958(2)0.0854(2)0.1049(2)0.1741(3)0.2010(3)0.1529(3)0.0693(3)0.0979(3)0.1825(3)0.0486(3)-0.0372(3)-0.0356(3)-0.0638(3)0.65380.56310.32790.43530.3270.26820.18590.21680.19440.1690.23890.27180.2440.20910.39270.4350.4550.4395 | 0.3256(4)0.4398(4)-0.0623(4)-0.0267(4)-0.0721(4)-0.1569(3)-0.[922(3)-0.2717(3)-0.3164(3)-0.2831(4)-0.2048(4)-0.3092(3)-0.3805(3)-0.4551(3)-0.5145(4)-0.5317(4)-0.2911(4)-0.2126(3)-0.1760(4)-0.1758(4)-0.2000(4)-0.2099(4)-0.0996(5)0.26410.1609-0.00950.04880.19650.23180.17590.22290.0339-0.0061-0.06080.32330.25240.23460.08450.04720.12430.4778 | 1.1757(3)1.1698(3)1.2788(2)1.3252(2)1.3239(2)1.2743(2)1.2292(2)1.1775(2)1.1729(2)1.2175(2)1.2675(2)1.1298(2)1.0681(2)1.0931(2)1.0297(2)1.1503(2)0.9556(2)0.9055(2)0.9214(2)0.8498(2)0.8247(3)1.1011(3)1.0812(3)0.9240.85610.90110.84821.42931.0451.03181.10731.15761.07921.12791.31991.25321.32481.45781.38971.45461.2098 | 4.8(1)7.4(2)4.4(1)4.8(1)4.6(1)37(1)3.41(10)3.27(10)3.5(1)4.1(1)4.4(1)3.65(10)4.0(1)4.1(1)5.7(1)5.4(1)4.4(1)4.1(1)5.7(1)4.9(1)6.2(1)5.1(1)9.0(2)6.43846.07926.10975.989811.6416.23866.23866.23867.22627.22627.226210.588210.588210.588211.641611.641611.64168.8793 |
H(19)H(20)H(21)H(22)H(23)H(24)H(25)H(26)H(27)H(28)H(29)H(30)H(31)H(32)H(33)H(34)H(35)H(36)H(37)H(38)H(39)H(40)H(41)H(42)H(43)H(44) | 0.42650.35660.13750.25760.35110.34240.07170.1590.21510.24590.14150.10750.19640.20770.20970.1838-0.0675-0.0427-0.0559-0.0373-0.0525-0.11950.46090.36530.05220.0593 | 0.46830.44640.0305-0.048-0.3146-0.1828-0.1257-0.5585-0.4647-0.5575-0.4926-0.5722-0.5784-0.2102-0.1935-0.101-0.1364-0.2289-0.2502-0.0502-0.0831-0.09530.14090.0238-0.347-0.4211 | 1.12621.16961.35761.35641.21291.29810.82071.00770.99531.04661.19131.13121.16440.96390.88180.92850.82450.77730.85661.11491.0341.08211.14461.15551.1581.0497 | 8.87938.87935.75055.56484.90785.28385.93876.82186.82186.82186.42066.42066.42066.88966.88966.88967.44357.44357.443510.756910.756910.75694.96425.0854.38424.7834 |
KB-3-1细胞 | |||
药物 | 阿霉素(μM) | APC(μM) | 浓度比 |
A | 0.0108 | 129.3996 | 11981.44 |
B | 0.0216 | 129.3996 | 5990.72 |
C | 0.0431 | 129.3996 | 3002.31 |
D | 0.0862 | 129.3996 | 1501.16 |
E | 0.0862 | 64.6998 | 750.58 |
F | 0.0862 | 32.3499 | 375.29 |
G | 0.0862 | 16.1749 | 187.64 |
H | 0.0862 | 8.0875 | 93.82 |
I | 0.0862 | 4.0437 | 46.91 |
J | 0.0862 | 2.0219 | 23.46 |
KB-V1细胞 | |||
药物 | 阿霉素(μM) | APC(μM) | 浓度比 |
A | 1.0776 | 129.3996 | 120.08 |
B | 2.1552 | 129.3996 | 60.04 |
C | 4.3104 | 129.3996 | 30.02 |
D | 8.6208 | 129.3996 | 15.01 |
E | 8.6208 | 64.6998 | 7.51 |
F | 8.6208 | 32.3499 | 3.75 |
G | 8.6208 | 16.1749 | 1.88 |
H | 8.6208 | 8.0875 | 0.94 |
I | 8.6208 | 4.0437 | 0.47 |
J | 8.6208 | 2.0219 | 0.23 |
细胞系 | LD50(μM±SD) | |
阿霉素 | APC | |
KB-3-1KB-V1比值 | 0.0639±0.01063.0510±0.284647.7 | 41.9153±2.801617.2656±8.24410.41 |
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 01143860 CN1215070C (zh) | 2001-12-12 | 2001-12-12 | 前胡丙素在制备治疗肿瘤药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 01143860 CN1215070C (zh) | 2001-12-12 | 2001-12-12 | 前胡丙素在制备治疗肿瘤药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1425667A CN1425667A (zh) | 2003-06-25 |
CN1215070C true CN1215070C (zh) | 2005-08-17 |
Family
ID=4677259
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 01143860 Expired - Fee Related CN1215070C (zh) | 2001-12-12 | 2001-12-12 | 前胡丙素在制备治疗肿瘤药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1215070C (zh) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102784139B (zh) * | 2012-01-04 | 2015-05-06 | 安徽省食品药品检验所 | 一种治疗糖尿病伴高血脂症的药物组合物及其制备方法 |
CN103420990B (zh) * | 2012-05-23 | 2016-04-20 | 复旦大学 | 7-氧、硫或氮杂取代香豆素及其衍生物和用途 |
CN103275071B (zh) * | 2013-05-17 | 2015-04-15 | 山西大学 | 一种香豆素衍生物及其制备方法和用途 |
CN109438462B (zh) * | 2018-10-08 | 2021-04-20 | 广西中医药大学 | 具有抗肿瘤活性的o-对硝基苯甲酰基土甘草a及其制备方法和用途 |
CN109438463B (zh) * | 2018-10-08 | 2021-04-20 | 广西中医药大学 | 具有抗肿瘤活性的o-(4-溴-2-氟苯甲酰基)土甘草a、及制备方法和用途 |
CN109232599B (zh) * | 2018-10-08 | 2021-04-20 | 广西中医药大学 | 具有抗肿瘤活性的o-对三氟甲基苯甲酰基土甘草a及其制备方法和用途 |
CN109232601A (zh) * | 2018-10-08 | 2019-01-18 | 广西中医药大学 | 具有抗宫颈癌活性的土甘草a衍生物及其制备方法和用途 |
CN109438461B (zh) * | 2018-10-08 | 2021-04-20 | 广西中医药大学 | 具有抗白血病活性的土甘草a衍生物及其制备方法和用途 |
CN109232600B (zh) * | 2018-10-08 | 2021-04-20 | 广西中医药大学 | 具有抗肿瘤活性的o-对甲基苄基土甘草a、制备方法、及药物制剂和用途 |
CN109400618B (zh) * | 2018-11-09 | 2021-08-10 | 中国药科大学 | 一种色满衍生物及其制备方法和应用 |
-
2001
- 2001-12-12 CN CN 01143860 patent/CN1215070C/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1425667A (zh) | 2003-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Tewari et al. | Adverse drug reactions of anticancer drugs derived from natural sources | |
Dey et al. | Therapeutic value of steroidal alkaloids in cancer: Current trends and future perspectives | |
Choi et al. | Podophyllotoxin acetate triggers anticancer effects against non-small cell lung cancer cells by promoting cell death via cell cycle arrest, ER stress and autophagy | |
Peng et al. | Identification and biological activities of new taccalonolide microtubule stabilizers | |
CN1215070C (zh) | 前胡丙素在制备治疗肿瘤药物中的应用 | |
Škubník et al. | Mitotic poisons in research and medicine | |
Subash-Babu et al. | Epoxy clerodane diterpene inhibits MCF-7 human breast cancer cell growth by regulating the expression of the functional apoptotic genes Cdkn2A, Rb1, mdm2 and p53 | |
Zhou et al. | Paris saponin VII extracted from trillium tschonoskii suppresses proliferation and induces apoptosis of human colorectal cancer cells | |
Tang et al. | Anti-Tumor xanthones from Garcinia nujiangensis suppress proliferation, and induce apoptosis via PARP, PI3K/AKT/mTOR, and MAPK/ERK signaling pathways in human ovarian cancers cells | |
Li et al. | Croton tiglium extract induces apoptosis via Bax/Bcl-2 pathways in human lung cancer A549 cells | |
Knockleby et al. | Cytotoxic and anti-plasmodial activities of Stephania dielsiana YC Wu extracts and the isolated compounds | |
Ding et al. | Quercus acutissima Carruth. root extract triggers apoptosis, autophagy and inhibits cell viability in breast cancer cells | |
Mallya et al. | Cytotoxic activity and initiation of apoptosis via intrinsic pathway in jurkat cells by leaf extract of Zanthoxylum rhetsa DC | |
Liu et al. | Retracted Article: Synthesis of xanthone derivatives and anti-hepatocellular carcinoma potency evaluation: induced apoptosis | |
Lalrinzuali et al. | Sonapatha (Oroxylum indicum) mediates cytotoxicity in cultured HeLa cells by inducing apoptosis and suppressing NF-κB, COX-2, RASSF7 and NRF2 | |
Bhowmick et al. | The anti-mycobacterial activity of Artemisia annua L is based on deoxyartemisinin and artemisinic acid | |
Yamgar et al. | An update on drug discovery and natural products | |
Bartnik et al. | Evaluation of the Biological Effect of Non-UV-Activated Bergapten on Selected Human Tumor Cells and the Insight into the Molecular Mechanism of Its Action | |
CN1216616C (zh) | 中药白花前胡在制备治疗肿瘤药物中的应用 | |
Mahato et al. | Plant-based natural products in cancer therapeutics | |
Wang et al. | Molecular mechanism of the anti-gastric cancer activity of 1, 2, 3, 6-tetra-O-galloyl-β-D-glucose isolated from Trapa bispinosa Roxb. shell in vitro | |
CN1580043B (zh) | 抗恶性肿瘤南柴胡萃取物的制备方法 | |
Pan et al. | Gancao Nurish-Yin Decoction medicated serum inhibits growth and migration of ovarian cancer cells: Network pharmacology-based analysis and biological validation | |
Püsküllüoğlu et al. | The therapeutic potential of natural metabolites in targeting endocrine-independent HER-2-negative breast cancer | |
Diaz-Allen | Developing a 1D-TOCSY NMR-Based Dereplication Technique to Facilitate the Isolation of New, Cytotoxic Compounds from Natural Products |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: HONG KONG CITY UNIV Free format text: FORMER OWNER: FANG HONGXUN; HU YAOCHANG Effective date: 20061229 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20061229 Address after: Da Tong Road, Kowloon Tong, Hongkong Patentee after: City University of Hong Kong Address before: Department of biology and chemistry, Kowloon City University, Hongkong Co-patentee before: Hu Yaochang Patentee before: Fang Hongxun |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050817 Termination date: 20171212 |
|
CF01 | Termination of patent right due to non-payment of annual fee |